PharmTech Europe News

Feb 24, 2017
By Pharmaceutical Technology Editors
The agency’s CHMP recommended conditional marketing authorization for the hormone replacement therapy for the treatment of chronic hypoparathyroidism.
Feb 24, 2017
By Pharmaceutical Technology Editors
The agency’s CHMP recommended six drugs for market approval, including one orphan drug, during its February meeting.
Feb 21, 2017
PTSM: Pharmaceutical Technology Sourcing and Management
By Pharmaceutical Technology Editors
Under the agreement, Abzena will manufacture magacizumab, an antibody created using the ‘Abzena inside’ Composite Human Antibody technology.
Feb 20, 2017
By Pharmaceutical Technology Editors
BPS-804, which is being developed for the treatment of osteogenesis imperfecta (brittle bone disease), has been granted orphan drug designation by both FDA and the European Commission.
Feb 17, 2017
PTSM: Pharmaceutical Technology Sourcing and Management
By Pharmaceutical Technology Editors
Sartorius and EMBL have entered into a corporate partnership program to foster advanced training.
Feb 15, 2017
By Pharmaceutical Technology Editors
Baricitinib (Olumiant) is the first JAK inhibitor licensed to treat rheumatoid arthritis in Europe.
Feb 15, 2017
By Pharmaceutical Technology Editors
The directorate says monographs are flexible and changeable and their compliance does not on its own determine biosimilarity in biosimilars.
Feb 10, 2017
Pharmaceutical Technology spoke with Tommy Fanning, head of biopharmaceuticals for IDA Ireland, to get a perspective on how Brexit may affect the pharmaceutical industry.
Feb 10, 2017
By Pharmaceutical Technology Editors
EMA announces that the European Union’s PAS Register has received its 1000th upload.
Feb 01, 2017
By Pharmaceutical Technology Editors
Novo Nordisk entered a research collaboration with the University of Oxford focused on Type 2 diabetes.
native1_300x100
lorem ipsum